The Centers for Medicare and Medicaid Services (CMS) just shared a preliminary list of generic drugs it plans to make available to Medicare recipients for $2 in a pilot program. The program ...

Two generic drugmakers, Apotex and Heritage Pharmaceuticals, have agreed to pay a combined $49 million to settle allegations they fixed prices on numerous medicines, the first such agreements ...

But a generic version (and the active ingredient) of this popular medication, sildenafil, is widely available from several drug manufacturers at a fraction of the cost. Read on to find out more ...

Viatris' generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been ...

The Centers for Medicare & Medicaid Services (CMS) released a list of prescription drugs it hopes to include in its new Medicare $2 Drug List Model, the agency announced Wednesday. Designed to ...

By Reed Abelson and Rebecca Robbins Insulin for $35 a month. A limit of $2,000 a year in out-of-pocket drug costs for older Americans. Billions of dollars in savings for Medicare resulting from ...

Axios reports the Biden administration today will release a preliminary list of generic drugs for Medicare recipients that would cost no more than $2 out of pocket. The pilot program aims to test drug ...

The drug is part of a new generation of treatments that are reaching market, substantially expanding the options patients with the condition have. Roche’s Hemlibra has become a new preventive standard ...

Oct 9 (Reuters) - The U.S. Centers for Medicare & Medicaid Services released on Wednesday a preliminary list of 101 generic drugs that would be available for no more than $2 for a month's supply ...

The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic ...

In a year-long Phase 3 trial, the company tested the drug, called apitegromab, on top of existing treatments for the disease. Among the main population studied, children ages 2 to 12, treated ...